Erratum: Warfarin dose prediction in children using pharmacometric bridging - Comparison with published pharmacogenetic dosing algorithms(European Journal of Clinical Pharmacology (2013):69:1275-1283 DOI 10.1007/s00228-012-1466-4);Warfarin dose prediction in children using pharmacometric bridging - Comparison with published pharmacogenetic dosing algorithms

European Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2013, Pages 1275-1283

  Hamberg, Anna Karin ^a   Friberg, Lena E ^a   Hanséus, Katarina ^b   Ekman Joelsson, Britt Marie ^c   Sunnegårdh, Jan ^c   Jonzon, Anders ^d   Lundell, Bo ^e   Jonsson, E Niclas ^a,f   Wadelius, Mia ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^d UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Exprimo NV   (Belgium)

Author keywords

Children; Dosing; PK PD model; Population analysis; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ACCURACY; ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLOMETRY; ARTICLE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ETHNIC GROUP; FEMALE; GENE; GENETIC ALGORITHM; GENOTYPE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDISH; VKORC1 GENE;

EID: 84878018047     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1565-x     Document Type: Erratum

References (25)

1. Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, Vesely SK (2012) Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 suppl):e737S-e801S
2. Monagle P, Newall F, Campbell J (2010) Anticoagulation in neonates and children: Pitfalls and dilemmas. Blood Rev 24(4-5):151-162
3. Young G (2011) Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med 16(6):349-354
4. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792
5. Gage B, Eby C, Johnson J, et al. (2008) Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clin Pharmacol Ther 84(3):326-331
6. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753-764
7. Lenzini P, Wadelius M, Kimmel S, et al. (2010) Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clin Pharmacol Ther 87(5):572-578
8. Avery PJ, Jorgensen A, Hamberg A-K, Wadelius M, Pirmohamed M, Kamali F (2011) A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy. Clin Pharmacol Ther 90(5):701-706
9. van Schie RM, Wadelius M, Kamali F, et al. (2009) Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10):1687-1695
10. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg JH, COAG Investigators (2010) Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 1-9
11. Do EJ, Lenzini P, EBY CS,, et al.. (2011) Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 1-8
12. Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, Mitchell LG (2010) In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 116(26):6101-6105
13. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, Beaune P, Cheurfi R, Bonnet D, Loriot MA (2012) Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 119(3):861-867
14. Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, Leathart JBS, Hanley JP, Daly AK, Kamali F (2012) VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 119(3):868-873
15. Holford N (2010) Dosing in children. Clin Pharmacol Ther 87(3):367-370
16. Takahashi H (2000) Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 68(5):541-555
17. Kato Y, Ichida F, Saito K, Watanabe K, Hirono K, Miyawaki T, Yoshimura N, Horiuchi I, Taguchi M, Hashimoto Y (2011) Effect of the VKORC1 Genotype on Warfarin Dose Requirements in Japanese Pediatric Patients. DMPK 26(3):295-299
18. Meibohm B, Läer S, Panetta JC, Barrett JS (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7(2):E475-87
19. Edginton AN (2010) Knowledge-driven approaches for the guidance of first-in-children dosing. Pediatric Anesthesia 21(3):206-213
20. Cella M, Gorter de Vries F, Burger D, Danhof M, Pasqua Della O (2010) A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 87(3):294-302
21. Hamberg A-K, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN (2007) A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 81(4):529-538
22. Hamberg A-K, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN (2010) A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 87(6):727-734
23. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models. AAPS J 13(2):143-151
24. Bauer RJ (2011) NONMEM User's Guide. Icon Development Solutions, Ellicott City, pp 1-128
25. Jönsson S, Karlsson MO (2005) Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug. Eur J Pharm Sci 25(1):123-132